Biomarkers

Applications and trends that are revolutionising drug discovery and development

August 2010
Biomarkers: Applications and trends that are revolutionising drug discovery and development

August 2010

ISBN: 978 1 85822 391 9

© Copyright 2010 Espicom Business Intelligence

All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping or storage in information retrieval systems without the express permission of the publisher.

Every care has been taken to ensure that the information contained in this report is correct. The publisher accepts no liability for decisions made on the basis of information contained herein.

British Library Cataloguing in Publication Data.

A catalogue record for this report is available from the British Library.
# Chapter 4 - Applications of Biomarkers in Drug Discovery & Development

## Executive Summary

Application of biomarkers in identifying new drug targets

### Functiona...
Chapter 6 - Players, Alliances & Acquisitions

Executive Summary

Players, alliances & acquisitions

Chapter 7 - Outlook & Future of Biomarker Research

Executive Summary

Outlook & Future of Biomarker Research

OUTLOOK & FUTURE OF BIOMARKER RESEARCH

Market trends & forecasts

Increased collaboration

Increased numbers of qualified biomarkers & surrogate endpoints

Explore new therapeutic areas & rare diseases

Adoption of new technologies in biomarker identification & qualification

Increased number of companion-diagnostic programmes

Regulatory guidance & harmonisation

Financial investment in biomarker R&D

Biomarker impact near, mid and long-term

Table 17: Factors affecting the impact of biomarkers on the industry over the near, mid & long-term
List of Tables
Table 1: Fit for purpose criteria ................................................................................................................................. 5
Table 2: Biomarker sample types – advantages, limitations & recommendations.......................................................... 28
Table 3: Pre-analytical & analytical bias of samples & data.......................................................................................... 30
Table 4: Drug discovery & development based on genomics targets ........................................................................... 43
Table 5: Biomarkers surrogate endpoints for safety .................................................................................................... 62
Table 6: Personalised medicine vs. traditional medicine ............................................................................................. 65
Table 7: Approved personalised medicines .................................................................................................................. 65
Table 8: Personalised medicine market .......................................................................................................................... 66
Table 9: Leading biomarker discovery & development companies .............................................................................. 74
Table 10: Summary of major pharmaceutical company biomarker alliances ............................................................... 79
Table 11: Exploratory biomarkers for cancer .................................................................................................................. 81
Table 12: Exploratory biomarkers for cardiovascular diseases ....................................................................................... 81
Table 13: Exploratory biomarkers for CNS disorders .................................................................................................. 82
Table 14: Exploratory biomarkers of inflammatory diseases ......................................................................................... 83
Table 15: Key biomarker diagnostic company alliances .............................................................................................. 84
Table 16: Key academia & consortia alliances .................................................................................................................. 84
Table 17: Factors affecting the impact of biomarkers on the industry over the near, mid & long-term ......................... 92
Table 18: Biomarker market forecast (US$mn) ................................................................................................................ 93
Table 19: Summary of ones to watch in biomarker R&D & commercialisation ............................................................. 94
Table 20: Recent biomarker alliances & developments in cancer .................................................................................... 98
Table 21: Recent biomarker alliances and developments in cardiovascular disease .................................................. 100
Table 22: Recent biomarker alliances & developments in CNS disorders ..................................................................... 100
Table 23: Recent biomarker alliances & developments in immune/inflammatory disorders ...................................... 101

List of Charts
Figure 1: Pharma R&D activity & attrition rates (1995-2009) ......................................................................................... 6
Figure 2: Advantages of biomarker discovery in drug discovery & development ........................................................... 7
Figure 3: Role of Biomarkers in drug discovery & development ...................................................................................... 8
Figure 4: Initiatives in biomarker discovery & development .......................................................................................... 9
Figure 5: Shift in attrition rates to early phase .................................................................................................................. 10
Figure 6: Risk-based classification of VPDs ................................................................................................................... 11
Figure 7: Voluntary genomic data submissions: process & outcomes ........................................................................... 16
Figure 8: Preliminary biomarker qualification process .................................................................................................. 17
Figure 9: Multidisciplinary biomarker discovery, validation & qualification process ....................................................... 25
Figure 10: Multidisciplinary biomarker discovery – a collaborative effort ...................................................................... 26
Figure 11: Types of R&D biomarkers ............................................................................................................................ 27
Figure 12: Protein Quantitation - MS based proteomics ................................................................................................. 31
Figure 13: Technological advances in proteomics increases data generation ............................................................... 32
Figure 14: Systems biology approach to biomarkers ..................................................................................................... 35
Figure 15: Migration from traditional R&D model to translational R&D Model .............................................................. 41
Figure 16: Different phases of translational research ..................................................................................................... 42
Figure 17: PBS-Bio real-time computer imaging technology ............................................................................................ 48
Figure 18: Percent risk associated with different stages of drug development ............................................................... 53
Figure 19: Early drug development process .................................................................................................................. 54
Figure 20: Patient enrichment trial designs ................................................................................................................... 59
Figure 21: Relationship between biomarker and clinical outcome dependent on biomarker ......................................... 61
Figure 22: Relationship between biomarker and clinical outcome independent of biomarker ....................................... 61
Figure 23: Relationship between biomarker and clinical outcome on long term prognosis ........................................ 62
Figure 24: Medical product (Rx)/Diagnostic (Dx) development models ........................................................................ 64
Figure 25: Traditional medical product (Rx)/Diagnostic (Dx) development models ....................................................... 64